Documents

Aims for mid-single digit CAGR and five blockbuster launches by 2030, driving broad portfolio growth.

Q2 2026 sales up 7%, Wegovy pill drives growth, guidance raised amid U.S. pricing pressure.

CagriSema, Zenagamtide, and UBT251 deliver strong clinical results; key readouts due 2026–2027.

Strong Q1 sales growth and product launches offset by price pressures; 2026 guidance raised.

Strong growth, leadership changes, and strategic focus on innovation amid rising competition.

CagriSema missed non-inferiority to Tirzepatide in REDEFINE 4, with 23% vs 25.5% weight loss.

Renewed focus on diabetes and obesity, with innovation in higher dose and oral therapies.

Wegovy pill launch drove rapid growth amid pricing pressures and strong capital returns.

2026 guidance forecasts a 5–13% decline in adjusted sales and profit amid U.S. pricing headwinds.

New board elected amid governance changes, with plans to restore independence by 2026.

Sharpened focus on obesity and diabetes, robust pipeline, and new launches to drive future growth.